Therefore, our aim was to examine the use of GFAP as an early clinical marker of HIE severity in full-term neonates by determining expression in umbilical cord blood (UCB) samples from healthy control infants, infants with perinatal asphyxia, and infants with HIE. The gene discussed is GFAP; the disease is perinatal asphyxia.